ACTU 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ACTU ▼ -3.34% at T+5d

NEUTRAL call ✗ call lost -3.34% · α vs SPY -4.48% · entry $2.99 → $2.89

Next anchor: T+20d in 11d

Last close $2.38 (close May 22) · -20.40% from $2.99 entry

Entry anchored
May 6, 09:44 AM ET
via Databento tick

T+1d

+11.71%

call +11.71% · α +12.04%

$3.34

settled 17d ago

T+5d

-3.34%

call -3.34% · α -4.48%

$2.89

settled 11d ago

T+20d

—

call — · α —

—

in 11d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Actuate Therapeutics appointed Martin H. Huber, MD, as an independent director, expanding the board from 7 to 8 members. The appointment is routine but comes 30 days after proxy fight materials (DEFA14A), suggesting it may be related to board composition negotiations. No financial impact.

Actionable Insight

The appointment may be a response to activist pressure from the proxy contest. Monitor for further board changes, settlement announcements, or a definitive proxy statement. The expanded board with an industry veteran could stabilize governance but does not change fundamentals.

Key Facts

Martin H. Huber, MD, appointed to board effective May 1, 2026, filling a newly created seat (board expanded from 7 to 8 directors).
Dr. Huber will serve as a Class III director until the 2027 annual meeting.
Compensation includes 30,000 stock options (3-year vesting), $44,000 annual retainer, and $3,000 quarterly consulting fee for R&D advisory services.
Dr. Huber previously served as CEO of Mersana Therapeutics (acquired by Day One Biopharmaceuticals) and held senior R&D roles at Xilio, TESARO, and Merck.
The filing follows a DEFA14A (proxy fight materials) filed 30 days earlier, indicating an ongoing board contest.

Financial Impact

Immaterial; director compensation is standard and consulting fee is $12,000 per year.

Risk Factors

Ongoing proxy contest may lead to further board turnover or distracting shareholder activism.
Dr. Huber's consulting role (R&D advisory) introduces potential conflicts or additional compensation scrutiny.
No financial guidance or operational updates provided in this filing.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001683168-26-003515
Document: actuate_ex9901.htm	0001683168-26-003515
Document: 0001683168-26-003515-index-headers.html	0001683168-26-003515
Document: 0001683168-26-003515-index.html	0001683168-26-003515
Document: 0001683168-26-003515.txt	0001683168-26-003515

5 reports for ACTU

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ACTU — sortable, filterable
	Type				Now
May 11, 2026 12d ago	8-K MIXED ★ 7/10	$2.89 $2.43	▼ −15.92%	▼ −15.99%	$2.38 (−17.65%)
May 6, 2026 17d ago	DEFA14A NEUTRAL ★ 4/10	$2.99 $2.89	▼ −3.34%	▼ −4.48%	$2.38 (−20.40%)
May 6, 2026 17d ago	8-K NEUTRAL ★ 4/10	$2.99 $2.89	▼ −3.34%	▼ −4.48%	$2.38 (−20.40%)
Apr 14, 2026 5w ago	Press Release BULLISH ★ 8/10	$2.08 $2.27	▲ +8.89%	▲ +7.50%	$2.38 (+14.42%)
Mar 9, 2026 10w ago	Press Release NEUTRAL ★ 4/10	$2.95 $2.68	▼ −9.00%	▼ −7.64%	$2.38 (−19.19%)

US Market Status

Market Closed — Opens Tue (34h 48m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access